^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

RPL22L1 overexpression

i
Other names: RPL22L1, Ribosomal Protein L22 Like 1, Large Ribosomal Subunit Protein EL22-Like 1, 60S Ribosomal Protein L22-Like 1, Ribosomal Protein L22-Like 1
Entrez ID:
4ms
RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma. (PubMed, Cell Death Dis)
Our study identified a novel candidate oncogene RPL22L1 which promoted the GBM malignancy through STAT3 pathway. And we highlighted that Stattic combined with TMZ therapy might be an effective treatment strategy in RPL22L1 high-expressed GBM patients.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • RPL22L1 (Ribosomal Protein L22 Like 1) • RPL22 (Ribosomal Protein L22)
|
RPL22L1 overexpression
|
temozolomide
7ms
Ribosomal Protein L22-Like1 (RPL22L1) as a Novel Biomarker for the Pathogenesis and Classification of Triple-Negative Breast Cancer (CAP 2023)
We demonstrated that high RPL22L1 expression is significantly associated with breast cancer, particularly in TNBC. Loss of RPL22L1 expression in carcinoma with medullary pattern highly indicates that medullary carcinoma is a pathologically and biologically distinct subtype of invasive breast carcinoma. Our findings suggest that RPL22L1 may be a novel and valuable biomarker for the pathogenesis and classification of TNBC.
RPL22L1 (Ribosomal Protein L22 Like 1) • RPL22 (Ribosomal Protein L22)
|
RPL22L1 overexpression
1year
Overexpression of ribosomal L22-like1 (RPL22L1) enhances cancer stem cell properties and promotes tumor progression in hepatocellular carcinoma (HCC) (AACR 2023)
Furthermore, higher RPL22L1 expression can also promote cell proliferation and epithelial-mesenchymal-transition, as well as drug resistance to 5-Fluorouracil (5-FU) and cisplatin (CDDP). The expression of RPL22L1 was also associated with adverse prognosis in HCC clinical samples. In conclusion, our study reveals aberrant ribosomal protein activity in HCC and the role of RPL22L1 in promoting HCC tumor progression.
Cancer stem
|
SOX9 (SRY-Box Transcription Factor 9) • RPL22L1 (Ribosomal Protein L22 Like 1)
|
CD44 expression • CD133 expression • RPL22L1 overexpression
|
cisplatin • 5-fluorouracil
over1year
Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma. (PubMed, Cell Death Discov)
Importantly, the ERK inhibitor (ERKi) could potentiate sorafenib efficiency in RPL22L1-high HCC cells. In summary, these data uncover RPL22L1 is a potential marker to guide precision therapy for utilizing ERKi to enhance the sorafenib efficacy in RPL22L1-high HCC patients.
Journal
|
RPL22L1 (Ribosomal Protein L22 Like 1)
|
RPL22L1 overexpression
|
sorafenib
over1year
Long-Read Nanopore Sequencing Identifies Mismatch Repair-Deficient Related Genes with Alternative Splicing in Colorectal Cancer. (PubMed, Dis Markers)
Our results showed that ONT-identified genes provide a pool to explore AS-associated markers for dMMR/MSI CRC. We demonstrated INHBA as a promising signature for clinical application in predicting tumor lymphatic metastasis and screening dMMR/MSI candidates.
Journal • Mismatch repair
|
MSI (Microsatellite instability) • RPL22L1 (Ribosomal Protein L22 Like 1) • HMGCS2 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 2)
|
MSI-H/dMMR • RPL22L1 overexpression